Imidazo[1,5-b]pyridazine-d4T conjugates: Synthesis and anti-human immunodeficiency virus evaluation

Antiviral Chemistry and Chemotherapy

Volumn 9, Issue 3, 1998, Pages 205-223

  Renoud Grappin, M ^a   Fossey, C ^a   Fontaine, G ^a   Laduree D ^a   Aubertin, A M ^b   Kirn, A ^b  

^a CENTRE D ETUDES ET DE RECHERCHE SUR LE MÉDICAMENT DE NORMANDIE   (France)

^b INSERM   (France)

Author keywords

d4T analogues; Heterodimers; HIV 1; Imidazo 1,5 b pyridazine; Reverse transcriptase

Indexed keywords

NUCLEOSIDE ANALOG; PYRIDAZINE DERIVATIVE; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE;

ANTIVIRAL ACTIVITY; ARTICLE; DRUG CONJUGATION; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NONHUMAN; PRIORITY JOURNAL;

EID: 0031779622     PISSN: 09563202     EISSN: None     Source Type: Journal    
DOI: 10.1177/095632029800900302     Document Type: Article

References (86)

1. Baba M, Pauwels R, Herdewijn P, De Clercq E, Desmyter J * Vandeputte M (1987a) Both 2′,3′-dideoxythymidine and its 2′,3′-unsaturated derivative (2′,3′-didehydro-2′,3′-dideoxythymidine) are potent and selective inhibitors of human immunodeficiency virus replication in vitro. Biochemical and Biophysical Research Communications 142:128-134.
2. Baba M, Pauwels R, Balzarini J, Herdewijn P & De Clercq E (1987b) The inhibition of human immunodeficiency virus (HIV) by 3′-azido-2′,3′-dideoxyguanosine in vitro. Biochemical and Biophysical Research Communications 145:1080-1086.
3. Baba M, Tanaka H, De Clercq E, Pauwels R, Balzarini J, Schols D, Nakashima H, Perno CF, Walker RT & Miyasaka T (1989) Highly specific inhibition of human immunodeficiency virus type 1 by a novel 6-substituted acyclouridine derivative. Biochemical and Biophysical Research Communications 165:1375-1381.
4. Baba M, De Clercq E, Tanaka H, Ubasawa M, Takashima H, Sekiya K, Nitta I, Umezu K, Nakashina H, Mori S, Shigeta S, Walker RT & Miyasaka T (1991) Potent and selective inhibition of human immunodeficiency virus type 1 (HIV-1) by 5-ethyl-6-phenylthiouracil derivatives through their interaction with the HIV-1 reverse transcriptase. Proceedings of the National Academy of Sciences, USA 88:2356-2360.
5. Balzarini J, Kang GJ, Dalal M, Herdewijn P, De Clercq E, Broder S & Johns DG (1987) The anti-HTLV, anti-HIV and cytotoxic activity of 2′,3′-didehydro-2′,3′-dideoxyribonucleosides. A comparison with their parental 2′,3′-dideoxyribonucleosides. Molecular Pharmacology 32:162-167.
6. Balzarini J, Pauwels R, Baba M, Herdewijn P, De Clercq E, Broder S & Jonhs DG (1988a) The in vitro and in vivo anti-retrovirus activity and intracellular metabolism of 3′-azido-2′,3′-dideoxythymidine and 2′,3′-dideoxycytidine are highly dependent on the cell species. Biochemical Pharmacology 37:897-903.
7. Balzarini J, Pauwels R, Baba M, Herdewijn P & De Clercq E (1988b) Anti-retrovirus activity of 3′-fluoro and 3′-azido substituted pyrimidine-2′,3′-dideoxynucleoside analogues. Biochemical Pharmacology 37:2847-2856.
8. Balzarini J, Naesens L & Herdewijn P (1989) Marked in vivo antiretrovirus activity of 9-(2-phosphonylmethoxyethyl)adenine, a selective anti-human immunodeficiency virus agent. Proceedings of the National Academy of Sciences, USA 86:332-336.
9. Balzarini J, Pérez-Pérez MJ, San Felix A, Schols D, Perno CF, Vandamme AM, Camarasa MJ & De Clercq E (1992) 2′,5′-Bis-O-(tert-butyldimethylsilyl)-3′-spiro5″- (4″-amino-1″,2″-oxathiole-2″,2″dioxide) pyrimidine (TSAO) nucleoside analogues. Highly selective inhibitors of human immunodeficiency virus type 1 that are targeted at the viral reverse transcriptase. Proceedings of the National Academy of Sciences, USA 89:4398-4396.
10. Balzarini J, Karlsson A, Pérez-Pérez MJ, Vrang L, Walbers J, Zhang H, Öberg B, Vandamme AM, Camarasa MJ & De Clercq E (1993a) HIV-1-specific reverse transcriptase inhibitors show differential activity against HIV-1 mutant strains containing different amino acid substitutions in the reverse transcriptase. Virology 192:246-253.
11. Balzarini J, Karlsson A, Pérez-Pérez MJ, Camarasa MJ, Tarpley WG & De Clercq E (1993b) Treatment of human immunodeficiency virus type 1 (HIV-1)-infected cells with combinations of HIV-1-specific inhibitors results in a different resistance pattern than does treatment with single-drug therapy. Journal of Virology 67:5353-5359.
12. Boyer PL, Currens MJ, McMahon JB, Boyd MR & Hugues SH (1993) Analysis of non-nucleoside drug-resistant variants of human immunodeficiency virus type I reverse transcriptase. Journal of Virology 67:2412-2420.
13. Browne MJ, Mayer KH, Chafee SB, Dudley MN, Posner MR, Steinberg SM, Graham KK, Geletko SM, Zinner SH, Denman SL Dunkle LM, Kaul S, McLaren C, Skowron G, Kontlab NM, Kennedy TA, Weitberg AB & Curt GA (1993) 2′,3′-didehydro-3′-deoxythymidine (d4T) in patients with Aids or Aids related complex, a phase I trial. Journal of Infectious Diseases 167:21-29.
14. Buckheit RW, White EL, Germany-Decker J, Allen LB, Ross LJ, Shannon WM, Janssen PAJ & Chirigos MA (1994) Cell-based and biochemical analysis of the anti-HIV activity of combination of 3′-azido-3′-deoxythymidine and analogues of TIBO. Antiviral Chemistry & Chemotherapy 5:35-42.
15. Camarasa MJ, Pérez-Pérez MJ, San-Felix A, Balzarini J & De Clercq E (1992) 3′-spiro nucleosides, a new class of specific human immunodeficiency virus type I inhibitors: synthesis and antiviral activity of [2′,5′-bis-O-(tert-butyldimethylsilyl)-β-D-xylo and ribofuranose]-3′-spiro-5″-[(4″-amino-l″,2″- oxathiole-2″,2″-dioxide) pyrimidine and pyrimidine modified nucleosides. Journal of Medicinal Chemistry 35:2988-2995.
16. 50, synergism, antagonism, low-dose risk, receptor binding and enzyme kinetics. In Computer Software for Apple II Series and IBM-PC and Instruction Manual, pp. 19-28. Cambridge: Elsevier-Biosoft.
17. Classon B, Per J & Garegg B (1982) A facile preparation of 2′,3′-unsaturated nucleoside and hexopyranosides from acetylated halohydrins by reductive elimination. Acta Chemica Scandanavica B 36:251-253.
18. Cretton EM, Xie MY, Bevan RJ, Goodgaon NM, Schinazi RF & Sommadossi JP (1991) Catabolism of 3′-azido-3′-deoxythymidine in hepatocytes and liver microsomes with evidence of formation of 3′-amino-3′-deoxythymidine, a highly toxic catabolite for human bone marrow cells. Molecular Pharmacology 39:258-266.
19. De Clercq E (1992) HIV inhibitors targeted at the reverse transcriptase. AIDS Research and Human Retroviruses 8:119-134.
20. De Clercq E (1994) HIV resistance to reverse transcriptase inhibitors. Biochemical Pharmacology 47:155-169.
21. De Vreese K, Debyser Z, Vandamme AM, Pauwels R, Desmyter J & De Clercq E (1992) Resistance of human immunodeficiency virus type 1 reverse transcriptase to TIBO derivatives induced by site-directed mutagenesis. Journal of Virology 188:900-904.
22. Divita G, Müller B, Immendörfer U, Gautel M, Rittinger K, Restle T & Goody RS (1993) Kinetics of interaction of HIV reverse transcriptase with primer/template. Biochemistry 32:7966-7971.
23. Emini EA, Starzewski S, Schneider CL, Waterbury JA, Schleif WA, Goehler R, Deussen A, Duerr S, Massari FE, Calandra GB, Hoffstedt B & Byrnes VW (1993) Combination therapy with AZT prevents selection of HIV-1 variants that are highly resistant to the nonnucleoside reverse transcriptase inhibitor L-697,661. Antiviral Research 20 (Suppl. 1):94.
24. Fischl MA, Richman DD, Grieco MH, Gottlieb MS, Volberding PA, Laskin OL, Leedom JM, Mildvan D, Schooley RT, Jackson GC, Durack DT & King D (1987) The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. New England Journal of Medicine 317:185-191.
25. Gao Q, Gu Z, Parniak MA, Lin X & Wainberg MA (1992) In vitro selection of variants of human immunodeficiency virus type 1 resistant to 3′-azido-3′-deoxythymidine. Journal of Virology 66:12-19.
26. Goldman ME, Nunberg JH, O'Brien JA, Quintero JC, Schleif WA, Freund KF, Gaul SL, Saari WS, Wai JS, Hoffman JM, Anderson PS, Haye DJ, Emini EA & Stern AM (1991) Pyridinone derivative: specific human immunodefiency virus type 1 reverse transcriptase inhibitors with antiviral activity. Proceedings of the National Academy of Sciences, USA 88:6863-6867.
27. Grob PM, Wu JC, Cohen KA & Merluzzi VJ (1993) Nonnucleoside inhibitors of HIV-1 reverse transcriptase nevirapine as a prototype drug. AIDS Research and Human Retroviruses 8:145-152.
28. Hanasaki Y, Watanabe H, Katsuura K, Takayama H, Shirakawa S, Yamaguchi K, Sakai S, Ijichi K, Fujiwara M, Konno K, Yokota T, Shigeta S & Baba M (1995) Thiadiazole derivatives: highly potent and specific HIV-1 reverse transcriptase inhibitors. Journal of Medicinal Chemistry 38:2038-2040.
29. Hizi A, Tal R, Shahabany M, Currens MJ, Hugues SH & McMahon JB (1993) Specific inhibition of the reverse transcriptase of human immunodeficiency virus type I and the chimeric enzymes of human immunodeficiency virus type I and type II by nonnucleoside inhibitors. Antimicrobial Agents & Chemotherapy 37:1037-1042.
30. Ijichi K, Fujiwara M, Mori K, Morozumi M, Machida H, Shigeta S, Konno K, Yokota T & Baba M (1996) Antiviral activities of nucleotide heterodimers against human immunodeficiency virus type 1 in vitro. Antiviral Research 31:115-120.
31. Ikeda K, Tanaka S & Mizuno Y (1975) Syntheses of 5-carbomethoxymethyl- and 5-methylamino-methyl-2-thiouridine (the 'first letters' of some anticodons) and closely related nucleosides from uridine. Chemical and Pharmaceutical Bulletin 23:2958-2964.
32. Japour AJ, Chatis PA, Eigenrauch HA & Crumpaker CS (1991) Detection of human immunodeficiency virus type I clinical isolates with reduced sensitivity to zidovudine and dideoxyinosine by RNA-RNA hybridation. Proceedings of the National Academy of Sciences, USA 88:3092-3096.
33. Kellam P, Boucher CAB & Larder BA (1992) Fifth mutation in human immunodeficiency virus type 1 reverse transcriptase contributes to development of high-level resistance to zidovudine. Proceedings of the National Academy of Sciences, USA 89:1934-1938.
34. Kohlstaedt LA, Wang J, Friedman JM, Rice PA & Steizt TA (1992) Crystal structure at 3.5Å of HIV-1 reverse transcriptase complexed with an inhibitor. Science 256:1783-1790.
35. Koup RA, Merluzzi VJ, Hargrave KD, Adams J, Grozinger K, Eckner K & Sullivan JL (1991) Inhibition of human immunodeficiency virus type 1 (HIV-1) replication by the dipyridodiazepinone BI-RG-587. Journal of Infectious Diseases 163:966-970.
36. Larder BA, Darby G & Richman DD (1989) HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy. Science 243:1731.
37. Larder BA & Kemp SD (1989) Multiple mutation in HIV-1 reverse transcriptase confer high level resistance to zidovudine (AZT). Science 246:1155.
38. Larder BA (1992) 3′-azido-3′-deoxythymidine resistance suppressed by a mutation conferring human immunodeficiency virus type 1 resistance to non-nucleoside reverse transcriptase inhibitors. Antimicrobial Agents & Chemotherapy 36:2664-2669.
39. Lefebvre I, Périgaud C, Pompon A, Aubertin AM, Girardet JL, Kirn A, Gosselin G & Imbach JL (1995) Mononucleoside phosphotriester derivatives with S-acyl-2-thioethyl bioreversible phosphate-protecting groups: intracellular delivery of 3′-azido-2′,3′-dideoxythymidine 5′-monophosphate. Journal of Medicinal Chemistry 38:3941-3950.
40. Lin T, Schinazi RF & Prusoff WH (1987) Potent and selective in vitro activity of 3′-deoxythymidin-2-ene (3′-deoxy-2′,3′-didehydrothymidine) against human immunodeficiency virus. Biochemical Pharmacology 36:2713-2718.
41. Livermore DHG, Bethell RC, Cammack N, Hancock AP, Hann MM, Green DVS, Lamont RB, Noble SA, Orr DC, Payne JJ, Ramsay VJ, Shingler AH, Smith C, Storer R, Williamson C & Willson T (1993) Synthesis and anti HIV-1 activity of a series of imidazo[1,5-b]pyridazines. Journal of Medicinal Chemistry 36:3784-3794.
42. Mansuri MM, Starrett JE, Ghazzouli I, Hitchcock MJM, Sterzycki RZ, Brankovan V, Lin T, August EM, Prusoff WH, Sommadossi J & Martin JC (1989a) 1-(2,3-dideoxy-β-D-glycero-pent-2-enofuranosyl) thymine. A highly potent and selective HIV agent. Journal of Medicinal Chemistry 32:461-466.
43. Mansuri MM, Starrett JE Jr, Wos JA, Tortolani DR, Brodfuehrer PR, Howell HG & Martin JC (1989B) Preparation of 1-(2,3-dideoxy-β-D-glycero-pent-2-enofuranosyl) thymine d4T and 2′,3′-dideoxyadenosine (ddA): general methods for the synthesis of 2′,3′-olefinic and 2′,3′-dideoxy nucleoside analogues active against HIV. Journal of Organic Chemistry 4780-4785.
44. 4 acetyl-cytidine. Chemical and Pharmaceutical Bulletin 22:128-134.
45. Maury G & Divita G (1995) Les progrès récents dans la connaissance de la structure de la transcriptase inverse du virus d'immunodéficience humaine suggèrent-ils la conception et la synthèse de nouveaux inhibiteurs de l'enzyme et de nouvelles drogues anti-SIDA. Bulletin de la Societe Chimique de France 132:1095-1102.
46. Merigan TC, Skowron G, Bozzette SA, Richman DD, Rittamchandani R, Fischl MA, Schooley RT, Hirch M, Soo W, Pettinelli C & Schaumburg H (1989) The ddC study group of the AIDS clinical trials group circulating p24 antigen levels and responses to dideoxycytidine in human immunodeficiency virus (HIV) infections. Annals of Internal Medicine 110:189-194.
47. Mellors JW, Dutschman GE, Im GJ, Tramontano E, Winkler SR & Cheuq YC (1992) In vitro selection and molecular characterization of human immunodeficiency virus-1 resistant to non nucleoside inhibitors of reverse transcriptase. Molecular Pharmacology 41:446-451.
48. Merluzzi VJ, Hargrave KD, Labadia M, Grozinger K, Skoog M, Wu JC, Shih CK, Eckner K, Hattox S, Adams J, Rosenthal AS, Faanes R, Eckner RJ, Koup RA & Sullivan JC (1990) Inhibition of HIV-1 replication by a non nucleoside reverse transcriptase inhibitor. Science 250:1411-1413.
49. Mitsuya H, Weinhold KJ, Furman PA, St Clair MH, Nusinoff Lehrman S, Gallo RC, Bolognesi D, Barry DW & Broder S (1985) 3′-azido,3′-deoxythymidine (BWA 509 U): an antiviral agent that inhibits the infectivity and cytopathic effect of human T-lymphotropic virus type III/lymphadenopathy associated virus in vitro. Proceedings of the National Academy of Sciences, USA 82:7096-7100.
50. Mitsuya H, Yarchoan R & Broder S (1990) Molecular targets for Aids therapy. Science 249:1533-1544.
51. Miyasaka T, Tanaka H, Baba M, Hayakawa H, Walker RT, Balzarini J & De Clercq E (1989) A novel lead for specific anti HIV-1 agents 1-[(2 hydroxyethoxy) methyl]-6-(phenylthio)thymine. Journal of Medicinal Chemistry 32:2507-2509.
52. Moog C, Wick A, Le Ber P, Kirn A & Aubertin AM (1994) Bicyclic imidazo derivatives, a new class of highly selective inhibitors for the human immunodeficiency virus type 1. Antiviral Research 24:275-288.
53. Mosmann T (1983) Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. Journal of Immunological Methods 65:55-63.
54. Müller B, Restle T, Reinstein J & Goody RS (1991) Interaction of fluorescently labelled dideoxynucleotides with HIV-1 reverse transcriptase. Biochemistry 30:3709-3715.
55. Nanni RG, Ding J, Jaccobo-Molina A, Hughes SH & Arnold E (1993) Review of HIV-1 reverse transcriptase three-dimensional structure: implication for drug design. Perspectives in Drug Disscovery and Design 1:129-150.
56. Nunberg JH, Schleif WA, Boots EJ, O'Brien JA, Quintero JC, Hoffman JM, Emini EA & Goldman ME (1991) Viral resistance to human immunodeficiency virus type 1-specific pyridinone reverse transcriptase inhibitors. Journal of Virology 65:4887-4892.
57. Pauwels R, Balzarini J, Schols D, Baba M, Desmyter J, Rosenberg I, Holý A & De Clercq E (1988) Phosphonylmethoxyethyl purine derivative, a new class of anti-human immunodeficiency virus agents. Antimicrobial Agents and Chemotherapy 32:1025-1030.
58. Pauwels R, Andries K, Desmyter J, Schols D, Kukla MJ, Breslin HJ, Raeymaeckers A, Van Gelder J, Woestenborghs R, Heykants J, Schellekens K & Janssen PA (1990) Potent and selective inhibition of HIV-1 replication in vitro by a novel series of TIBO derivatives. Nature 343:470-474.
59. Pauwels R, Andries K, Debysser Z, Van Daele P, Schols D, Stoffels K, De Vreese R, Woestenborgh AM, Vandamme CC, Janssen J, Anne G, Cauwenbergh J, Desmyter J, Heykant M, Janssen GM, Janssen AC, De Clercq E & Janssen PA (1993) Potent and highly selective human immunodeficiency virus type 1 (HIV-1) inhibition by a series of α-anilinophenylacetamide derivatives targeted at HIV-1 reverse transcriptase. Proceedings of the National Academy of Sciences, USA 90:1711-1715.
60. Pauwels R, Andries K, Debyser Z, Kukla MJ, Schols D, Breslin HJ, Woestenborghs R, Desmyter J, Janssen MAC, De Clercq E & Janssen PAJ (1995) New tetrahydroimidazo[4,5,1-jk] [1,4]-benzodiazepin-2 (1-H)-one-thione derivatives are potent inhibitors of human immunodeficiency virus type 1 replication and are synergistic with 2′,3′-dideoxynucleoside analogs. Antimicrobial Agents and Chemotherapy 38:2863-2870.
61. Pugazhenthi U, Delbaere LT, Kumar SVP, Stuart AL & Gupta SV (1994) 2′,3′-didehydro-2′,3′-dideoxy-5-hydroxymethyluridine. Acta Crystallographica C 50:1262-1265.
62. Richman DD, Frichl MA, Grieco MH, Gottlieb MS, Volberding PA, Laskin OL, Leedom JM, Groopman JE, Mildvan D, Hirsch MS, Jackson GG, Durack DT & Nusinoff-Lehrman S (1987) AZT collaborative working group. The toxicity of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS related complex. New England Journal of Medicine 317:192-197.
63. Richman D, Shih CK, Lowry I, Rose J, Prodanovich P, Goffs S & Griffiri J (1991) Human immunodeficiency virus type 1 mutants resistant to non-nucleoside inhibitors of reverse transcriptase arise in tissue culture. Proceedings of the National Academy of Sciences, USA 88:11241-11245.
64. Riddler SA, Anderson RE & Mellors JW (1995) Antiretroviral activity of stavudine (2′,3′-didehydro-3′-deoxythymidine d4T). Antiviral Research 27:189-203.
65. Robbins MJ, Hansske F, Low NH & Park JI (1984) A mild conversion of vicinal diols to alkenes. Efficient transformation of ribonucleosides into 2′-ene and 2′,3′-dideoxynucleosides. Tetrahedron Letters 25:367.
66. Romero DL, Busso M, Tan CK, Reusser F, Palmer JR, Poppe SM, Aristoff PA, Downey KM, So AG, Resnick L & Tarpley WG (1991) Non nucleoside reverse transcriptase inhibitors that potently and specifically block human immunodeficiency virus type 1 replication. Proceedings of the National Academy of Sciences, USA 88:8806-8810.
67. Romero DL, Morge RA, Gerrin MJ, Biles C, Basso M, Resnick L, Althaus IW, Reusser F, Thomas RC & Tarpley WG (1993) Bis(heteroaryl)piperazine (BHAP) reverse transcriptase inhibitors: structure-activity relationships of novel substituted indole analogues and the identification of 1-[(5-methanesulfonamido-1H-indol-2-yl)-carbonyl]-4-[3-(1-methylethyl)amino]- pyridinyl piperazine monomethane sulfonate (U-90152S) a second-generation clinical candidate. Journal of Medicinal Chemistry 36:1505-1508.
68. Rong FG & Soloway AH (1994) Synthesis of 5-tethered carborane-containing pyrimidine nucleosides as potential agents for DNA incorporation. Nucleosides and Nucleotides 13:2021-2034.
69. Rong FG, Soloway AH, Ikeda S & Ives DH (1995) Synthesis and biochemical activity of 5-tethered carborane-containing pyrimidine nucleosides as potential agents for DNA incorporation. Nucleosides & Nucleotides 14:1873-1887.
70. Ruth JL & Cheng YC (1981) Nucleoside analogues with clinical potential in anti-virus chemotherapy. The effect of several thymidine and 2′-deoxycytidine analogue 5′-triphosphates on purified human (α, β) and herpes simplex virus (type 1, 2) DNA polymerases. Molecular Pharmacology 20:415-422.
71. Ruth JL & Cheng YC (1982) Selective antiviral agents. The metabolism of 5-propyl-2′-deoxyuridine and effects on DNA synthesis in herpes simplex virus type 1 infections. Journal of Biological Chemistry 257:10261-10266.
72. Sandström EG, Byinton RE, Kaplan JC & Hirsch MS (1985) Inhibition of T-cell lymphotropic virus type III in vitro by phosphonoformate. Lancet i:4075-4079.
73. Scheit KH (1966) Die synthese der 5′-diphosphate von 5-methyl-uridin, 5-hydroxy methyl-uridin und 3,5-dimethyl-uridin. Chemische Berichte 99:3884-3891.
74. Schinazi RF, Chu CK, Peck A, McMillan A, Mathias R, Cannon D, Jong LS, Beach JW, Chain B, Jeola S & Liotta DC (1992) Activities of the form optical of 2′,3′-dideoxy-3′-thiacytidine BCH-189 against human immunodeficiency virus type 1 in human lymphocytes. Antimicrobial Agents & Chemotherapy 36:672-676.
75. Sekine M, Seio K, Satoh T, Sakamoto K & Yokoyama S (1993) Synthesis of uridylyl (3′-5′) uridine derivatives containing 5-(methylamino-methyl) uridine as a modified nucleoside found from E. Coli minor tRNA. Nucleosides & Nucleotides 12:305-321.
76. Sommadossi JP & Carlisle R (1987) Toxicity of 3′-azido-3′-deoxythymidine and 9-(1,3 dihydroxy-2-propoxymethyl) guanine for normal human hematopoietic progenitor cells in vitro. Antimicrobial Agents & Chemotherapy 31:452-454.
77. Sonders H, Yao Q, Belleau B, Kraus JL, Nguyen-Ba N, Spira B & Wainberg MA (1991) Anti-human immunodeficiency virus type 1 activity and in vitro toxicity of 2′-deoxy-3′-thiacytidine BCH-189, a novel heterocyclic nucleoside analog. Antimicrobial Agents & Chemotherapy 35:1386-1390.
78. Stagg MP, Cretton EM & Kidd L (1992) Clinical pharmacokinetics of 3′-azido-3′-deoxythymidine (zidovudine) and catabolites with formation of a toxic catabolite 3′-amino-3′-deoxythymidine. Clinical Pharmacology and Therapeutics 51:668-676.
79. St Clair MH, Martin JL, Tudor-Williams G, Bach MC, Vavro CL, King DM, Kellam P, Kemp SD & Larder BA (1991) Resistance to ddI and sensitivity to AZT induced by a mutation in HIV-1 reverse transcriptase. Science 253:1557.
80. Tanaka H, Baba M, Ubasawa M, Takashima H, Sekiya K, Nitta I, Shigeta S, Walker RT, De Clercq E & Miyasaka T (1991) Synthesis and anti HIV activity of 2-, 3- and 4-substituted analogues of 1-[2 hydroxyethoxy)methyl]-6-(phenylthio)thymine. Journal of Medicinal Chemistry 34:1394-1399.
81. Tanaka H, Takashima H, Ubasawa M, Sekiya K, Nitta I, Baba M, Shigeta S, Walker RT, De Clercq E & Miyasaka T (1992) Synthesis and antiviral activity of deoxy analogs of 1-[(2-hydroxyethoxy)methyl]-6-phenylthio thymine HEPT as potent and selective anti-HIV-1 agents. Journal of Medicinal Chemistry 35:4713-4719.
82. Velazquez S, Alvarez R, San-Felix A, Jimeno ML, De Clercq E, Balzarini J & Camarasa MJ (1995) Synthesis and anti-HIV activity of [AZT]-[TSAO] and [AZT]-[HEPT] dimers as potential multifunctional inhibitors of HIV-1 reverse transcriptase. Journal of Medicinal Chemistry 38:1641-1649.
83. Volberding PA, Lagakos SW, Koch MA, Pettinelli C, Myers MW, Booth DK, Balfour HH, Reichman RC, Bartlett JA, Hirch MS, Murphy RL, Hardy WD, Soeiro R, Fischl MA, Bartlett JG, Merigan TC, Hyslop NE, Richman DD, Valentine FT & Corey L (1990) The Aids clinical trials group of the national institute of allergy and infection diseases. Zidovudine in a symptomatic human immunodeficiency virus infection. New England Journal of Medicine 322:941-949.
84. Yarchoan R, Thomas RV, Main JP, McAter N, Dubinsky R, Mitsuya H, Lawley TJ, Safai B, Myers CE, Perno CF, Klecker RW, Wills RW, Fischl MA, McNeily MC, Pluda JM, Leuther M, Collins JM & Broder S (1988) Phase I studies of 2′,3′-dideoxycytidine in severe human immunodeficiency virus infection as a single agent and alternating with zidovudine AZT. Lancet i:76-81.
85. Yarchoan R, Mitsuya H, Thomas H, Pluda RV, Hartman JM, Perno NR, Marczyk CF, Allain KS, Johns JP & Broder DG (1989) In vivo activity against HIV and favorable toxicity profile of 2′,3′-dideoxyinosine. Science 245:412-415.
86. Young SD (1993) Non-nucleoside inhibitors of HIV-1 reverse transcriptase. Perpectives in Drug Discovery and Design 1:181-192.